Cargando…
A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples
BACKGROUND: VAR2CSA, a member of the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) family, mediates the binding of P. falciparum-infected erythrocytes to chondroitin sulfate A, a surface-associated molecule expressed in placental cells, and plays a central role in the pathogenesis of...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561619/ https://www.ncbi.nlm.nih.gov/pubmed/28818101 http://dx.doi.org/10.1186/s12936-017-1976-8 |
_version_ | 1783257863898005504 |
---|---|
author | Dara, Antoine Travassos, Mark A. Adams, Matthew Schaffer DeRoo, Sarah Drábek, Elliott F. Agrawal, Sonia Laufer, Miriam K. Plowe, Christopher V. Silva, Joana C. |
author_facet | Dara, Antoine Travassos, Mark A. Adams, Matthew Schaffer DeRoo, Sarah Drábek, Elliott F. Agrawal, Sonia Laufer, Miriam K. Plowe, Christopher V. Silva, Joana C. |
author_sort | Dara, Antoine |
collection | PubMed |
description | BACKGROUND: VAR2CSA, a member of the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) family, mediates the binding of P. falciparum-infected erythrocytes to chondroitin sulfate A, a surface-associated molecule expressed in placental cells, and plays a central role in the pathogenesis of placental malaria. VAR2CSA is a target of naturally acquired immunity and, as such, is a leading vaccine candidate against placental malaria. This protein is very polymorphic and technically challenging to sequence. Published var2csa sequences, mostly limited to specific domains, have been generated through the sequencing of cloned PCR amplicons using capillary electrophoresis, a method that is both time consuming and costly, and that performs poorly when applied to clinical samples that are commonly polyclonal. A next-generation sequencing platform, Pacific Biosciences (PacBio), offers an alternative approach to overcome these issues. METHODS: PCR primers were designed that target a 5 kb segment in the 5′ end of var2csa and the resulting amplicons were sequenced using PacBio sequencing. The primers were optimized using two laboratory strains and were validated on DNA from 43 clinical samples, extracted from dried blood spots on filter paper or from cryopreserved P. falciparum-infected erythrocytes. Sequence reads were assembled using the SMRT-analysis ConsensusTools module. RESULTS: Here, a PacBio sequencing-based approach for recovering a segment encoding the majority of VAR2CSA’s extracellular region is described; this segment includes the totality of the first four domains in the 5′ end of var2csa (~5 kb), from clinical malaria samples. The feasibility of the method is demonstrated, showing a high success rate from cryopreserved samples and more limited success from dried blood spots stored at room temperature, and characterized the genetic variation of the var2csa locus. CONCLUSIONS: This method will facilitate a detailed analysis of var2csa genetic variation and can be adapted to sequence other hypervariable P. falciparum genes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-017-1976-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5561619 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-55616192017-08-18 A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples Dara, Antoine Travassos, Mark A. Adams, Matthew Schaffer DeRoo, Sarah Drábek, Elliott F. Agrawal, Sonia Laufer, Miriam K. Plowe, Christopher V. Silva, Joana C. Malar J Research BACKGROUND: VAR2CSA, a member of the Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) family, mediates the binding of P. falciparum-infected erythrocytes to chondroitin sulfate A, a surface-associated molecule expressed in placental cells, and plays a central role in the pathogenesis of placental malaria. VAR2CSA is a target of naturally acquired immunity and, as such, is a leading vaccine candidate against placental malaria. This protein is very polymorphic and technically challenging to sequence. Published var2csa sequences, mostly limited to specific domains, have been generated through the sequencing of cloned PCR amplicons using capillary electrophoresis, a method that is both time consuming and costly, and that performs poorly when applied to clinical samples that are commonly polyclonal. A next-generation sequencing platform, Pacific Biosciences (PacBio), offers an alternative approach to overcome these issues. METHODS: PCR primers were designed that target a 5 kb segment in the 5′ end of var2csa and the resulting amplicons were sequenced using PacBio sequencing. The primers were optimized using two laboratory strains and were validated on DNA from 43 clinical samples, extracted from dried blood spots on filter paper or from cryopreserved P. falciparum-infected erythrocytes. Sequence reads were assembled using the SMRT-analysis ConsensusTools module. RESULTS: Here, a PacBio sequencing-based approach for recovering a segment encoding the majority of VAR2CSA’s extracellular region is described; this segment includes the totality of the first four domains in the 5′ end of var2csa (~5 kb), from clinical malaria samples. The feasibility of the method is demonstrated, showing a high success rate from cryopreserved samples and more limited success from dried blood spots stored at room temperature, and characterized the genetic variation of the var2csa locus. CONCLUSIONS: This method will facilitate a detailed analysis of var2csa genetic variation and can be adapted to sequence other hypervariable P. falciparum genes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-017-1976-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-08-17 /pmc/articles/PMC5561619/ /pubmed/28818101 http://dx.doi.org/10.1186/s12936-017-1976-8 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Dara, Antoine Travassos, Mark A. Adams, Matthew Schaffer DeRoo, Sarah Drábek, Elliott F. Agrawal, Sonia Laufer, Miriam K. Plowe, Christopher V. Silva, Joana C. A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples |
title | A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples |
title_full | A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples |
title_fullStr | A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples |
title_full_unstemmed | A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples |
title_short | A new method for sequencing the hypervariable Plasmodium falciparum gene var2csa from clinical samples |
title_sort | new method for sequencing the hypervariable plasmodium falciparum gene var2csa from clinical samples |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561619/ https://www.ncbi.nlm.nih.gov/pubmed/28818101 http://dx.doi.org/10.1186/s12936-017-1976-8 |
work_keys_str_mv | AT daraantoine anewmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT travassosmarka anewmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT adamsmatthew anewmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT schafferderoosarah anewmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT drabekelliottf anewmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT agrawalsonia anewmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT laufermiriamk anewmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT plowechristopherv anewmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT silvajoanac anewmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT daraantoine newmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT travassosmarka newmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT adamsmatthew newmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT schafferderoosarah newmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT drabekelliottf newmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT agrawalsonia newmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT laufermiriamk newmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT plowechristopherv newmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples AT silvajoanac newmethodforsequencingthehypervariableplasmodiumfalciparumgenevar2csafromclinicalsamples |